ArticlePharmacoEconomics - open2024
NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances.
Article in PharmacoEconomics - open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Decision-Analytic Modelling Approaches in Economic Evaluations of Post-traumatic Stress Disorder Treatments.PharmacoEconomics · 2026Pooled it
- Assessing cost-effectiveness in oncology treatment sequences: a review of pathway modeling methods for health technology assessment.International journal of technology assessment in health care · 2026Review
- Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's Disease.PharmacoEconomics · 2025Article
- Comment on "Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria".PharmacoEconomics · 2025Article
- Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria.PharmacoEconomics · 2025Review
- A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence.PharmacoEconomics · 2025Article
- A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States.MDM policy & practiceArticle
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.